Cancer risk assessment method based on glutaminolysis patterns, and use thereof

Through a method based on glutamine metabolism mode, the expression of GLS, KGA and GAC in peripheral blood leukocytes is used to evaluate cancer risk, solving the problems of low abundance of peripheral blood markers and complex extraction in the prior art, and achieving rapid Convenient and highly accurate cancer diagnosis.

WO2024245463A1PCT designated stage expired Publication Date: 2024-12-05SHENZHEN BAY LAB
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/107003
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-01
Filing Date
2024-07-23
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

In the existing cancer diagnosis technology, the abundance of circulating free DNA, exosomes and circulating tumor cells in peripheral blood is low, the extraction experiment is complex and costly, and there is a lack of low cost, low complexity and high accuracy based on peripheral blood white blood cells. Diagnostic technology.

Method used

Using a glutamine metabolism model method, the expression and expression ratio of GLS, KGA and GAC were detected to evaluate cancer risk, and the quantitative value of glutamine metabolism in peripheral blood leukocytes was used as a diagnostic marker to simplify experimental operations and reduce costs. .

Benefits of technology

It achieves the rapid, convenient and high accuracy of cancer risk assessment, reduces the difficulty and cost of experiments, is suitable for large-scale promotion, and provides a new direction of non-invasive diagnostic technology.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024107003_05122024_PF_FP_ABST
    Figure CN2024107003_05122024_PF_FP_ABST
Patent Text Reader

Abstract

A cancer risk assessment method based on glutaminolysis patterns, and the use thereof. The cancer risk assessment method comprises: collecting samples; detecting gene expression of glutaminolysis patterns in the samples; and determining the risk probability of tumors or cancerous cells in the bodies of all the people from the samples on the basis of the glutaminolysis patterns. The present method has few measured parameters and testing is quick and convenient; when quantification of the GLS gene is performed at the RNA level, same can be combined with a single-cell transcriptomics, and various cell types in complex tissue can be simultaneously quantified, thereby solving the problem of cell heterogeneity in a sample; glutaminolysis patterns of white blood cells circulating in peripheral blood can be used for cancer risk assessment, testing complexity thereof is very low, and the present invention differs from currently patented techniques for almost all non-invasive cancer diagnoses, and thus a new direction can be provided for cancer non-invasive diagnosis techniques; also, test difficulty and costs can be greatly reduced, and the present invention is suitable for large-scale popularization.
Need to check novelty before this filing date? Find Prior Art

Description

Cancer risk assessment method based on glutamine metabolism pattern and its application Technical Field

[0001] The present invention relates to the technical field of gene detection, and in particular to a cancer risk assessment method based on glutamine metabolism pattern and its application. Background Art

[0002] Cancer is a major threat to the lives of Chinese citizens. Early diagnosis and treatment can effectively improve the living conditions of cancer patients, making it an area of ​​national development that the country advocates for vigorous development. Investment institutions generally estimate that the early cancer screening market could reach hundreds of billions of yuan. Currently, many research institutions and companies are involved in cancer diagnostic technology, but few products have passed large-scale validation. The market is in great demand for low-cost, low-complexity, and highly accurate cancer screening and diagnostic technologies and products.

[0003] Non-invasive diagnostic technologies based on peripheral blood are currently the mainstream research direction, with the vast majority of solutions focusing on circulating free DNA, exosomes, and circulating tumor cells. However, the abundance of these materials in peripheral blood is very low, and extraction experiments are complex and costly. Furthermore, there is a large number of participants, resulting in fierce competition. In contrast, the field of cancer diagnosis currently pays very little attention to white blood cells, and there are almost no cancer diagnostic technologies based on peripheral blood white blood cells in the industry.

[0004] Glutamine is a crucial source of carbon and nitrogen for many biosynthetic processes and a vital resource for cellular metabolism. In humans, glutamine metabolism is primarily catalyzed by glutaminase (GLS, also known as GLS1) to produce glutamate. The GLS gene has two major isoforms: KGA (kidney-type glutaminase) and GAC (glutaminase C). GLS expression is approximately the sum of KGA and GAC. Recently, research linking glutamine metabolism with tumors and cancer has become a hot topic. Most existing reports focus on studying gene expression related to glutamine metabolism in tumors. For example, Chinese patent application CN 115932262 A discloses the use of glutamine synthetase (GS) as a marker for pancreatic ductal adenocarcinoma using tissue sections. Chinese patent application CN115825262 A discloses the use of serum small molecule metabolites, such as α-ketoglutarate (AKG), choline, γ-glutamylglutamine, lysophosphatidylcholine, glycerophosphatidylcholine, and taurine, to detect nasopharyngeal carcinoma. Chinese patent application CN114373510A discloses the use of a metabolic marker system selected from phenylacetylglutamine for the diagnosis or monitoring of lung cancer. However, current detection technologies for genetic testing typically rely on either tissue sampling, which is time-consuming, labor-intensive, and painful for patients, or serum sampling, which primarily uses small molecule metabolites as markers. There is an urgent need to research and develop a convenient, fast and non-invasive detection technology to assess cancer risk.

[0005] Summary of the Invention

[0006] In view of this, the main purpose of the present invention is to provide a cancer risk assessment method based on glutamine metabolic pattern and its application, in order to at least partially solve the above technical problems.

[0007] To achieve the above objectives, as a first aspect of the present invention, a method for evaluating cancer risk, infection status, vaccine efficacy, and / or drug efficacy based on glutamine metabolic patterns is proposed, comprising the following steps:

[0008] Collect samples;

[0009] The gene expression information of the glutamine metabolic pattern in the sample is detected, and based on the glutamine metabolic pattern, the risk probability of the presence of tumors or cancerous cells in the body of all the people in the sample, the infection status, the vaccine effect and / or the drug effect are evaluated and determined.

[0010] As a second aspect of the present invention, a composition of glutamine metabolic markers for assessing the risk of tumor or cancerous cells in the body, infection status, vaccine efficacy, and / or drug efficacy is provided, comprising:

[0011] The first marker is used to mark the expression of GLS;

[0012] The second marker is used to mark the expression of KGA;

[0013] The third marker is used to mark the expression of GAC;

[0014] The evaluation of the risk of tumor or cancerous cells existing in the body, infection status, vaccine effect and / or drug effect is achieved based on only one or more of the ingredients in the composition.

[0015] As a third aspect of the present invention, a nucleic acid library of glutamine metabolic markers for assessing the risk of tumor or cancerous cells in the body, infection status, vaccine efficacy, and / or drug efficacy is proposed, characterized by comprising:

[0016] The first marker is used to mark the expression of GLS;

[0017] The second marker is used to mark the expression of KGA;

[0018] The third marker is used to mark the expression of GAC;

[0019] The evaluation of the risk of tumor or cancerous cells in the body, infection status, vaccine effect and / or drug effect is achieved based on only one or more of the first marker, the second marker and the third marker.

[0020] As a fourth aspect of the present invention, a cancer risk assessment system is proposed, comprising:

[0021] Nucleic acid detection module, used for performing qualitative or quantitative genetic detection on samples containing nucleic acid;

[0022] A nucleic acid library, using the nucleic acid library described above;

[0023] The evaluation module is used to determine the risk probability of the presence of tumors or cancerous cells in the body of all the sample owners, infection status, vaccine effectiveness and / or drug effect based on the evaluation method described above.

[0024] As a fifth aspect of the present invention, a cancer risk assessment method based on glutamine metabolism pattern is proposed, comprising the following steps:

[0025] Collect samples;

[0026] detecting gene expression information of glutamine metabolism pattern of the sample;

[0027] A pre-trained machine learning model is used to assess the risk of tumors or cancerous cells in all sample members; wherein the machine learning model uses the expression levels and / or expression relationships of GLS, KGA, and GAC as labels; the machine learning model includes KNN, support vector machine, logistic regression, decision tree, random forest, and naive Bayes classification models.

[0028] As a sixth aspect of the present invention, a kit based on the glutamine metabolism model is proposed, characterized in that the kit determines the risk probability of the presence of tumors or cancerous cells in all the people in the sample by simply capturing the expression levels and / or expression relationships of GLS, KGA and GAC in the white blood cells, free RNA or free proteins of the sample to be tested.

[0029] Based on the above technical solutions, it can be seen that the cancer risk assessment method based on glutamine metabolism, the kit and the application thereof of the present invention have at least one of the following beneficial effects compared with the prior art:

[0030] 1. The present invention uses two parameters for quantification: the total expression level of GLS and the expression ratio between the two subtypes. This method uses fewer detection parameters and is convenient and quick to perform.

[0031] 2. The present invention can quantify the expression of GLS genes at the RNA level. This can be combined with single-cell transcriptomes to simultaneously quantify multiple cell types in complex tissues, thereby addressing the problem of cellular heterogeneity in samples.

[0032] 3. The inventors have discovered that the quantitative value of glutamine metabolism in peripheral blood leukocytes can be used as a cancer diagnostic marker. Extracting leukocytes from peripheral blood is simple and distinct from nearly all currently patented technologies for non-invasive cancer diagnosis. This method could open up new avenues for non-invasive cancer diagnosis while significantly reducing experimental difficulty and costs, making it suitable for large-scale deployment. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 shows the comparison and differences of the exons of KGA and GAC;

[0034] Figure 2 shows the division of glutamine metabolism patterns;

[0035] 3A-3C are comparative results of the expression levels of the GLS gene and its two isoforms obtained from samples collected in Example 1 of the present invention;

[0036] 4A-4D are comparative results of whole-transcriptome sequencing data of peripheral blood leukocytes from 17 liver cancer patients and 17 healthy controls in Example 2 of the present invention;

[0037] Figures 5A-5C are comparative results of peripheral blood leukocyte GLS expression in 12 patients with uncomplicated infection, 20 patients with sepsis (4 patients with post-treatment follow-up), 19 patients with septic shock (10 patients with post-treatment follow-up), and 40 healthy controls in Example 3 of the present invention.

[0038] Figures 6A-6C are comparative results of the peripheral blood leukocyte KGA / GAC ratios of 12 patients with uncomplicated infection, 20 patients with sepsis (4 patients with post-treatment follow-up), 19 patients with septic shock (10 patients with post-treatment follow-up), and 40 healthy controls in Example 3 of the present invention. DETAILED DESCRIPTION

[0039] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments and with reference to the accompanying drawings.

[0040] Unless otherwise defined herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, however, preferred methods and materials are described.

[0041] All patents and publications mentioned herein, including all sequences disclosed within such patents and publications, are expressly incorporated by reference.

[0042] Numerical ranges include the numbers defining the range.

[0043] The headings provided herein are not limitations of the various aspects or embodiments of the invention. Accordingly, the terms defined below are more fully defined in conjunction with the specification as a whole.

[0044] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0045] For clarity and ease of reference, certain terms are defined below.

[0046] As used herein, the term "sample" refers to a material or mixture of materials, typically, although not necessarily, in liquid form, which contains one or more analytes of interest.

[0047] As used herein, the term "nucleic acid sample" refers to a sample comprising nucleic acids. As used herein, nucleic acid samples can be complex because they comprise a variety of different molecules comprising sequences. Mammalian (e.g., mouse or human) genomic DNA is typical of complex samples. Complex samples can have more than 104, 105, 106, or 107 different nucleic acid molecules. DNA targets can be derived from any source, such as genomic DNA or artificial DNA constructs.

[0048] The term "nucleotide" is intended to include structures that contain not only the known purine and pyrimidine bases, but also other modified heterocyclic groups. These modifications include methylated purines or pyrimidines, acylated purines or pyrimidines, alkylated ribose or other heterocyclic compounds. In addition, the term "nucleotide" includes structures that contain haptens or fluorescent labels, and may contain not only conventional ribose and deoxyribose sugars but also other sugars. Modified nucleosides or nucleotides also include modifications of the sugar moiety, for example, where one or more hydroxyl groups are replaced by halogen atoms or aliphatic groups, or are functionalized as ethers, amines, etc.

[0049] The terms "nucleic acid" and "polynucleotide" are used interchangeably herein to describe polymers of any length composed of nucleotides, such as deoxyribonucleotides or ribonucleotides, e.g., greater than about 2 bases, greater than about 10 bases, greater than about 100 bases, greater than about 500 bases, greater than about 1000 bases, up to about 10,000 bases or more, and can be produced enzymatically or synthetically. Naturally occurring nucleotides include guanine, cytosine, adenine, and thymine (G, C, A, and T, respectively). DNA and RNA have deoxyribonucleotide and ribonucleotide sugar backbones, respectively.

[0050] As used herein, the term "plurality" includes at least 2. In some cases, a plurality can be at least 10, at least 100, at least 100, at least 10,000, at least 100,000, at least 106, at least 107, at least 108, or at least 109 or more.

[0051] If two nucleic acids are "complementary," every base of one nucleic acid will base pair with the corresponding nucleotide of the other nucleic acid. Two nucleic acids need not be completely complementary to hybridize to each other.

[0052] As used herein, the term "sequencing" refers to a method by which the identity of at least 10 consecutive nucleotides of a polynucleotide is obtained (e.g., the identity of at least 20, at least 50, at least 100, or at least 200 or more consecutive nucleotides).

[0053] As used herein, the term "next-generation sequencing" or "high-throughput sequencing" refers to so-called parallel synthesis sequencing or ligation sequencing platforms currently employed by Illumina, Life Technologies, Roche, MGI, etc. Next-generation sequencing methods may also include nanopore sequencing methods such as those commercialized by Oxford Nanopore Technologies, electrical detection-based methods such as Ion Torrent commercialized by Life Technologies, or single-molecule fluorescence-based methods such as those commercialized by Pacific Biosciences.

[0054] As used herein, the term "peripheral blood" refers to blood outside the bone marrow, i.e., blood in the blood vessels. Peripheral blood contains platelets, red blood cells, white blood cells, and the like. Peripheral blood can be used in clinical routine blood tests, biochemical tests, and serum immunoassays. Doctors use these tests and the results to diagnose or identify diseases.

[0055] As used herein, the term "cell-free RNA," also known as "circulating cell-free RNA" (cfRNA), refers to RNA circulating in the peripheral blood of a patient.

[0056] The term "non-invasive testing" as used herein refers to non-invasive genetic testing technology, which requires only venous blood collection and sequencing of cell-free gene fragments (e.g., cfDNA, cfRNA, etc.) in peripheral plasma using next-generation DNA sequencing technology. The sequencing results are then subjected to bioinformatics analysis to obtain genetic and disease information. Non-invasive testing was first used for prenatal testing to screen fetuses for three major chromosomal disorders, and has since been expanded to detect diseases such as tumors, cancer, Parkinson's disease, and Alzheimer's disease that may cause genetic changes.

[0057] The present invention involves the following gene detection methods:

[0058] 1. Whole transcriptome sequencing (RNA-seq technology)

[0059] RNA high-throughput sequencing (RNA-seq) is currently the most widely used high-throughput sequencing technology. RNA-seq can help understand differences in the expression of all genes under various comparative conditions. It can detect differences between normal and tumor tissues; differences in gene expression before and after drug treatment; and differences in gene expression between different tissues at different developmental stages, among other things. Among all the differences detected, the most common and frequently used is the detection of differences in the expression levels of all mRNAs. It can also detect differences in RNA structure, such as differences in mRNA splicing, commonly known as alternative splicing. It can also detect fusion genes and SNPs (Single Nucleotide Polymorphisoms) caused by single-point mutations in genes.

[0060] RNA sequencing methods

[0061] In RNA sequencing, ribosomal RNA (rRNA) accounts for approximately 95% of the total RNA, but it is extremely stable in various human tissues and organs. Therefore, ribosomal RNA needs to be removed, and the remaining 2%-3% of mRNA needs to be tested. The most widely used method in experiments is Illumina's Truseq RNA library construction method: First, taking advantage of the fact that mRNA in higher organisms all have poly(A) tails, magnetic beads with poly(T) probes are hybridized with total RNA; the poly(T) probes then bind to the mRNA with poly(A) tails; the magnetic beads are then recovered, and the poly(A)-tailed mRNA is eluted from the beads; the eluted mRNA is treated with a magnesium ion solution, which breaks down the mRNA fragments; reverse transcription is performed using random primers, and after reverse transcription into (first-strand) cDNA, the second-strand (cDNA) is synthesized, thereby obtaining double-stranded cDNA. Then, "Y"-shaped connectors are connected to both ends of the double-stranded cDNA to form a standard sequencing library that can be sequenced on a HiSeq sequencer.

[0062] 2. Single-cell transcriptome sequencing (including 10× platform)

[0063] Single cell RNA sequencing is a new technology that sequences transcriptomes at the single-cell level. It can study gene expression within individual cells while addressing the problem of cellular heterogeneity that cannot be solved by sequencing tissue samples, making it possible to analyze the behavior and mechanisms of individual cells and their relationship with the body.

[0064] The 10×Genomics single-cell transcriptome sequencing platform utilizes microfluidics, oil droplet encapsulation, and barcode labeling technologies to achieve high-throughput cell capture. It can isolate and label 500-10,000 single cells at a time, thereby obtaining 3' transcriptome information for each cell. It has the advantages of high cell throughput, low library construction costs, and a short capture cycle. This technology is primarily used for cell typing and identification of marker factors, enabling the division of cell populations and the detection of gene expression differences between cell populations. Furthermore, this technology can predict cell differentiation and study developmental trajectories, playing an increasingly important role in current disease, immunity, oncology, and tissue, organ, and developmental research.

[0065] 3. qPCR

[0066] Quantitative Real-time PCR (qPCR) is a method that uses fluorescent chemicals to detect the total amount of product after each polymerase chain reaction (PCR) cycle in a DNA amplification reaction. It is a method for quantitatively analyzing specific DNA sequences in the sample to be tested using internal or external reference methods.

[0067] Real-time PCR uses the accumulated fluorescence signal to monitor the PCR process in real time. Finally, a standard curve is used to quantify the unknown template. During the exponential phase of PCR amplification, the Ct value of the template is linearly correlated with the starting copy number of the template, providing the basis for quantification.

[0068] 4. Digital PCR

[0069] Digital PCR (dPCR) is a technique for absolute nucleic acid quantification. Compared to qPCR, digital PCR can directly count the number of DNA molecules, providing absolute quantification of the starting sample.

[0070] 5.ELISA

[0071] The enzyme-linked immunosorbent assay (ELISA, ELASA) is a qualitative or quantitative test that uses antibodies to bind and measure a target molecule. Similar to other immunoassays, monoclonal and polyclonal antibodies can be used to detect analytes (such as peptides, proteins, antibodies, and small molecules). The antibody is specific for the analyte, and a component, such as horseradish peroxidase (HRP), is directly or indirectly coupled to the antibody, providing a detection method and enabling possible signal amplification. This method can be used for single sample detection or high-throughput screening.

[0072] ELISA method and principle

[0073] The experimental setup varies slightly depending on the specific type of ELISA used. One of the simplest ELISA formats begins by immobilizing the antigen of interest to a solid surface. This is typically done using a 96-well or 384-well plate that passively binds to the protein. The antibody is then prepared by coupling it to an enzyme. Adding this conjugate to the sample allows the antibody to bind to the antigen. Bound material that is not specific for the antigen of interest can then be removed using a washing step. A substrate for the enzyme is then added to allow the substrate in the solution to react with the enzyme linked to the antibody, ultimately producing a color, fluorescence, or luminescence change that can be read to determine the amount of target in each sample.

[0074] ELISA can be used to quantify one or more antigens in a test sample. Due to the specificity of antibody reagents and the ease of detection, ELISA is often considered the gold standard for quantitative testing of biological samples. In the biomedical / biochemical fields, assays based on the ELISA principle, which utilizes antibody-antigen binding combined with signal amplification, are very common. In research laboratories, these assays can be used to quantify protein levels or pathway activation. In the clinic, ELISA has a variety of applications, including measuring biomarkers of drug therapy or cytokine levels in patient serum samples. ELISA is also applicable in plant biology and can be used to detect crop allergens. In addition to its research use, ELISA is widely used in diagnostic testing, including for viral infections, food allergens, toxicity, and cancer. Detecting infectious viruses using antibodies is a rapid clinical test that can be scaled up to allow simultaneous testing of multiple samples. These tests are typically performed on serum or blood samples, but can also be performed on cell or tissue lysates.

[0075] 6. Mass spectrometry

[0076] Mass spectrometry, a spectroscopic method parallel to spectroscopy, is widely used across various disciplines to identify compounds by preparing, separating, and detecting gas-phase ions. Mass spectrometry can provide a wealth of structural information in a single analysis, and the integration of separation techniques with mass spectrometry is a breakthrough in separation science. Among numerous analytical testing methods, mass spectrometry is considered a universal method with both high specificity and sensitivity, and is widely used.

[0077] A mass spectrometer generally consists of a sample introduction system, an ion source, a mass analyzer, a detector, and a data processing system. Mass spectrometry is an analytical method that measures the mass-to-charge ratio (mass-to-charge ratio) of ions. Its basic principle is to ionize the components of a sample in an ion source, generating charged ions with varying mass-to-charge ratios. These ions are then accelerated by an electric field to form an ion beam that enters a mass analyzer. Within the mass analyzer, electric and magnetic fields are used to cause these ions to disperse at opposite velocities, focusing them to produce a mass spectrum, thereby determining their mass.

[0078] 7. SIMOA

[0079] SIMOA (Single Molecular Array) technology, based on the Simoa HD-1 digital single-molecule immunoassay array analyzer developed by Quanterix, a Nasdaq-listed company in the United States, enables ultra-sensitive detection of biomarkers such as proteins and nucleic acids in serum and plasma. SIMOA will significantly advance early cancer detection, postoperative monitoring, and precision medicine. Its primary application areas include oncology, neurology, infectious diseases, and immune-inflammatory diseases.

[0080] How it works

[0081] The key to SIMOA technology lies in capturing and sealing immune complexes within a chip containing over 200,000 femtoliter-scale pores for reaction, significantly improving detection sensitivity. Simoa, also known as digital ELISA, boasts an average sensitivity over 1,000 times higher than traditional immunoassays. It can accurately analyze low-concentration biomarkers that are undetectable using traditional methods, opening up new research prospects in life science research, in vitro diagnostics, companion diagnostics, and blood screening.

[0082] Glutamine is an important source of carbon and nitrogen in many biosynthetic processes and a vital resource for cellular metabolism. In the human body, glutamine metabolism is primarily catalyzed by glutaminase (GLS, also known as GLS1) to produce glutamate. The GLS gene has two main subtypes, namely KGA (kidney-type glutaminase) and GAC (Glutaminase C), meaning that the expression of GLS is approximately the sum of KGA and GAC. The first 14 exons of KGA and GAC are identical, but GAC uses exon 15, while KGA uses exons 16-19. The specific differences are shown in Figure 1.

[0083] The difference in exon usage results in different RNA sequences of KGA and GAC, leading to different protein structures and significant differences in enzyme activity: GAC enzyme activity is higher, reaching thousands of times that of KGA.

[0084] When GLS expression is low, the system is considered to have very low glutamine metabolism (e.g., cells are about to die); when GLS expression is relatively high, the system can be divided into a metabolic pattern dominated by KGA (such as brain tissue cells) or a metabolic pattern dominated by GAC (such as cancer cells and stem cells) based on its KGA and GAC expression. When a system changes, such as differentiation or exposure to external stimuli, glutamine metabolism will change (i.e., "reprogramming"). Therefore, GLS expression and the relative expression of KGA and GAC can be used to quantitatively characterize changes in glutamine metabolism.

[0085] In the human body, most organs are connected to the circulatory system, and immune cells are dynamically exchanged between peripheral blood and organs. In cancer patients, the occurrence and development of tumors can trigger an immune response, causing the immune cells in their microenvironment to change and affect the state of the immune system in peripheral blood. This state has multiple possibilities, such as changes in a certain immune cell itself, or changes in the components of leukocytes, or changes in some free gene fragments in plasma, such as free RNA, free proteins, etc. As shown in Figure 2, the inventors have found that the glutamine metabolic pattern of a certain system (which can be cells / tissues / organs) can be quantitatively described by combining the expression of GLS and these two subtypes, so that the gene expression of the glutamine metabolic pattern in leukocytes, free RNA, and free proteins can be quantitatively investigated, and whether it changes in the peripheral blood leukocytes, free RNA, and free proteins of the tested person can be checked, so as to assess the risk of the test person suffering from cancer. The reason it's called a risk assessment is, on the one hand, because the glutamine metabolism pattern can very promptly reflect changes in the cells in the tested person's body, allowing for early predictions with a very high accuracy rate. On the other hand, because the peripheral blood tested is usually venous blood, which flows throughout multiple organs throughout the body, the cellular changes reflected in the body cannot directly determine which specific organ is affected. Therefore, it can only serve as an early warning signal for the presence of tumors or even cancerous cells in the human body. The specific organ with tumors or cancer requires further systemic examinations and pathological tissue biopsy (the gold standard for cancer diagnosis) to finally determine. Therefore, the method of the present invention cannot be used as a diagnostic method for diseases, but only as a risk assessment method.

[0086] Based on this, the present invention discloses a cancer risk assessment method based on glutamine metabolism pattern, comprising the following steps:

[0087] Collect samples;

[0088] The gene expression of the glutamine metabolic pattern in the sample is detected, and the risk probability of the presence of tumors or cancerous cells in all the people in the sample is determined based on the gene expression type of the glutamine metabolic pattern.

[0089] The sample can be a genetic material sample containing glutamine metabolic expression information, such as a blood sample, a urine sample, a tissue sample, etc., preferably a peripheral blood sample, especially a peripheral blood sample obtained by non-invasive detection, such as a venous blood sample; further preferably, white blood cells, free RNA, free protein, etc. separated from the peripheral blood sample.

[0090] Among them, for free nucleic acids (free RNA), conventional detection often encounters low levels in peripheral blood, insufficient stability and integrity of free nucleic acids, certain degradation, long library construction processes, and cumbersome operations. However, because the gene expression that needs to be detected is very small, the present invention is relatively less affected by the defects of free RNA detection itself. However, relatively speaking, since free RNA and free protein are directly exposed to plasma, they are more affected by the outside world than white blood cells (leukocytes), and the results of genetic testing using white blood cells with cell membranes are more accurate and no more complicated than free RNA and free protein in operation.

[0091] The glutamine metabolism expression of the sample may include, for example: (i) expression of GLS, (ii) expression of KGA, (iii) expression of GAC, (iv) ratio of KGA to GAC, for example, preferably log2(KGA / GAC), and / or (v) proportion of KGA or GAC in GLS, etc., and the glutamine metabolism pattern is determined based on some of the options.

[0092] Among them, the gene expression information of the glutamine metabolic pattern of the sample can be detected and quantified, for example, by RNA-seq technology, single-cell transcriptomics (including 10× platform), qPCR designed for the GLS gene and its two subtypes, digital PCR and other schemes, or quantitative analysis of the corresponding proteins (including but not limited to ELISA, mass spectrometry, SIMOA, etc.).

[0093] Among them, the method of determining the glutamine metabolism pattern based on some options includes:

[0094] (i) Determining the risk of cancer for all individuals in the sample based on the expression of GLS and comparing it with a preset threshold. The inventors studied the test data and found that when the expression of leukocyte GLS is very low, the patient is likely to have cancer. Therefore, the detection of GLS expression alone can also be used as an evaluation indicator.

[0095] (ii) Determining the glutamine metabolism pattern based on the expression of KGA and GAC, such as the ratio / proportion between the two, or log2(KGA / GAC), and comparing it with a preset threshold to determine the risk of cancer for all individuals in the sample;

[0096] (iii) The expression level of GLS is combined with the expression levels of KGA and GAC, and compared with a preset threshold to determine the risk of cancer for the individual in the sample. A specific determination method may include, for example, first determining whether the expression level of GLS is above a first threshold, and then comparing the expression levels of KGA and GAC to determine the risk of cancer for the individual in the sample based on the different metabolic patterns of KGA and GAC.

[0097] The present invention also discloses a composition of glutamine metabolic markers for cancer risk assessment and / or diagnosis, comprising:

[0098] The first marker is used to mark the expression of GLS;

[0099] The second marker is used to mark the expression of KGA;

[0100] The third marker is used to mark the expression of GAC;

[0101] Wherein, the cancer risk assessment is mainly achieved based on one or more of the compositions.

[0102] The judgment logic includes:

[0103] (i) Based solely on the expression level of GLS, the risk of cancer for the sample owner is determined by comparing it with a preset threshold. The inventors studied the test data and found that when the expression of leukocyte GLS is very low, the patient is likely to have cancer. Therefore, the detection of GLS expression alone can also be used as an evaluation indicator.

[0104] (ii) Determining the glutamine metabolism pattern based on the expression of KGA and GAC, such as the ratio / proportion between the two, or log2(KGA / GAC), and comparing it with a preset threshold to determine the risk of cancer for all individuals in the sample;

[0105] (iii) The expression level of GLS is combined with the expression levels of KGA and GAC, and compared with a preset threshold to determine the risk of cancer for the individual in the sample. A specific determination method may include, for example, first determining whether the expression level of GLS is above a first threshold, and then comparing the expression levels of KGA and GAC to determine the risk of cancer for the individual in the sample based on the different metabolic expressions of KGA and GAC.

[0106] The present invention also discloses a nucleic acid library of glutamine metabolic markers for cancer risk assessment and / or diagnosis, comprising:

[0107] The first marker is used to mark the expression of GLS;

[0108] The second marker is used to mark the expression of KGA;

[0109] The third marker is used to mark the expression of GAC;

[0110] Among them, the cancer risk assessment is mainly achieved based on one or more of the first marker, the second marker and the third marker, and the specific assessment method is as described above.

[0111] The present invention also discloses a composition of glutamine metabolic markers for evaluating the effects of infection, vaccines and / or drugs, comprising:

[0112] The first marker is used to mark the expression of GLS;

[0113] The second marker is used to mark the expression of KGA;

[0114] The third marker is used to mark the expression of GAC;

[0115] The assessment of infection, vaccine, and / or drug efficacy is primarily based on the first to third markers. The present invention has discovered that glutamine metabolism patterns can be used to monitor any changes that could elicit an immune response, including infection, vaccination, and drug treatment effects. The present method can be used to detect and / or monitor infection severity, treatment efficacy, vaccine effectiveness, and so on. This method is similar to the cancer risk assessment method, with the only difference being the specific application and initial state, which can be adapted based on the specific situation and values.

[0116] The present invention also discloses a method for evaluating the effects of infection, vaccine and / or drug, comprising the following steps:

[0117] Collect samples;

[0118] The gene expression information of the glutamine metabolic pattern of the sample is detected, and the infection degree, treatment effect, and whether the vaccine works for all the people in the sample are determined based on the glutamine metabolic pattern. That is, the changes in the glutamine metabolic pattern of tumor cells are used to judge the relevant infection degree, treatment effect, and whether the vaccine works.

[0119] The sample can be a genetic material sample containing gene expression information of glutamine metabolism pattern, such as a blood sample, a urine sample, a tissue sample, etc., preferably a peripheral blood sample, especially a venous blood sample obtained by non-invasive detection, and further preferably white blood cells, free RNA, free protein, etc. separated from the peripheral blood sample.

[0120] The gene expression information of the glutamine metabolism pattern of the sample may include, for example: (i) expression of GLS, (ii) expression of KGA, (iii) expression of GAC, (iv) the ratio of KGA to GAC, preferably log2(KGA / GAC), and / or (v) the proportion of KGA or GAC in GLS, etc. The glutamine metabolism type is determined based on some of the options.

[0121] The glutamine metabolism expression of the sample can be detected and quantified, for example, by RNA-seq technology, single-cell transcriptomics (including 10× platform), qPCR designed for the GLS gene and its two subtypes, digital PCR and other schemes, or by quantification of the corresponding proteins (including but not limited to ELISA, mass spectrometry, SIMOA, etc.).

[0122] Among them, the method of determining the glutamine metabolism pattern based on some options includes:

[0123] (i) Determine the glutamine metabolism pattern based on the expression of KGA and GAC, such as the ratio / proportion between the two, or log2(KGA / GAC), and compare it with a preset threshold to determine the infection, vaccine and / or drug effects of all the sample owners;

[0124] (ii) The expression level of GLS is combined with the expression levels of KGA and GAC, and compared with a preset threshold to determine the infection of the individual in the sample, and the effect of the vaccine and / or drug. A specific determination method may include, for example, first determining whether the expression level of GLS is above a first threshold, and then comparing the expression levels of KGA and GAC. Based on the different metabolic patterns of KGA and GAC, the infection of the individual in the sample, and the effect of the vaccine and / or drug are determined.

[0125] The present invention also discloses a cancer risk assessment system, comprising:

[0126] Nucleic acid detection module, used for performing qualitative or quantitative genetic detection on samples containing nucleic acid;

[0127] A nucleic acid library, using the nucleic acid library described above;

[0128] An assessment module is used to determine the risk of the sample owner suffering from cancer based on the assessment method described above.

[0129] Among them, the nucleic acid detection module is, for example, a detection system using RNA-seq technology, single-cell transcriptome (including 10× platform) technology, qPCR technology, digital PCR technology, ELISA technology, mass spectrometry technology, and SIMOA technology.

[0130] The present invention also discloses a machine learning model for cancer risk assessment based on glutamine metabolic patterns, comprising:

[0131] A machine learning model is established using the expression levels and / or expression relationships of GLS, KGA, and GAC as labels, and the machine learning model is trained using sample data, thereby obtaining a trained machine learning model for cancer risk assessment based on glutamine metabolic patterns.

[0132] The machine learning model includes, for example, KNN (K-nearest neighbor), SVM (support vector machine), logistic regression, decision tree, random forest, naive Bayesian, and other classification models. The present invention is not limited to a specific machine learning model; as long as it can achieve simple classification through sample training, the classification result can be single, such as simply determining the presence or absence of tumor cells, or multiple, such as further determining the early, middle, or late stage of tumor development based on different threshold ranges.

[0133] The present invention also discloses a cancer risk assessment method based on glutamine metabolism pattern, comprising the following steps:

[0134] Collect samples;

[0135] detecting gene expression of glutamine metabolism pattern in the sample;

[0136] The cancer risk of all the sample members was assessed using the trained machine learning model for cancer risk assessment based on glutamine metabolism patterns as described above.

[0137] The present invention also discloses a cancer risk assessment system based on glutamine metabolism pattern, comprising:

[0138] A nucleic acid detection module is used to perform qualitative or quantitative detection of the expression levels and / or expression relationships of GLS, KGA, and GAC in samples containing nucleic acids;

[0139] The machine learning model is trained on sample data using the expression levels and / or expression relationships of GLS, KGA, and GAC as labels;

[0140] The evaluation module inputs the expression levels and / or expression relationships of GLS, KGA and GAC detected by the nucleic acid detection module into the machine learning model to obtain the cancer risk assessment results of the sample owner.

[0141] The nucleic acid detection module is, for example, a detection system using RNA-seq technology, single-cell transcriptome (including 10× platform) technology, qPCR technology, digital PCR technology, ELISA technology, mass spectrometry technology, or SIMOA technology;

[0142] The assessment module of the cancer risk assessment system can be implemented in the form of hardware or in the form of a software program module. When implemented in the form of a software program module and sold or used as an independent product, it can be stored in a computer-readable memory. Based on this understanding, the technical solution of the present invention, or the part that contributes to the prior art, or all or part of the technical solution can be embodied in the form of a software product. The computer software product is stored in a memory and includes several instructions for enabling a computer device (which can be a personal computer, server, or network device, etc.) to perform all or part of the steps of the method described in each embodiment of the present invention. The aforementioned memory includes various media that can store program code, such as a USB flash drive, a read-only memory (ROM), a random access memory (RAM), a mobile hard disk, a magnetic disk, or an optical disk.

[0143] The evaluation module may also be hardware, for example, a circuit, including digital circuits, analog circuits, and the like. Physical implementations of the hardware structure include, but are not limited to, physical devices, including, but not limited to, transistors, memristors, and the like. The computing module in the computing device may be any appropriate hardware processor, such as a CPU, GPU, FPGA, DSP, and ASIC. The storage unit may be any appropriate magnetic or magneto-optical storage medium, such as RRAM, DRAM, SRAM, EDRAM, HBM, HMC, and the like.

[0144] The present invention also discloses a cancer risk assessment kit based on glutamine metabolism pattern, which determines the risk probability of all the sample owners suffering from tumors or cancer by only capturing the expression levels and / or expression relationships of GLS, KGA and GAC on white blood cells, free RNA or free proteins in the sample to be tested.

[0145] The kit includes upstream and downstream primers (upstream and downstream probe sets) for specifically capturing the detection genes present in the sample to be tested and determining the expression levels and / or expression relationships of GLS, KGA and GAC. Further preferably, the upstream and downstream primer pairs are as follows: for KGA, 5'-actggagatgtgtctgcac-3' (Forward, SEQ ID NO: 1) and 5'-gcaggcttccagcaaaaat-3' (Reverse, SEQ ID NO: 2) can be used; for GAC, 5'-ttggactatgaaagtctccaac-3' (Forward, SEQ ID NO: 3) and 5'-ccattctatatactacagttgtagagat-3' (Reverse, SEQ ID NO: 4) can be used; for GLS, the sum of KGA and GLS can be taken, or they can be measured separately, such as using the following primers: 5'-atgcattcctgtggcatgt-3' (Forward, SEQ ID NO: 5) and 5'-ctgttgcccatcttatccagag-3' (Reverse, SEQ ID NO: 6). For greater accuracy, the expression of genes such as GAPDH, ACTB, and Actin can be used as a reference to normalize the expression levels of GLS, GKA, and GAC. For example, the Actin probes: 5'-agagctacgagctgcctgac-3' (Forward, SEQ ID NO: 7) and 5'-agcactgtgttggcgtacag-3' (Reverse, SEQ ID NO: 8) can be used. The upstream and downstream primers are not limited thereto. As long as the target marker can be captured, the primers can be designed in a variety of ways. Since the target sequence is very short, many primer design schemes are possible. However, as long as the target design of the present invention is adopted, it will be included in the scope of the present invention.

[0146] The kit further comprises a PCR plate coated with poly-dT primers and provided with sites for detecting GLS, KGA and GAC.

[0147] The kit further includes a result presentation unit for capturing and amplifying the target detection gene based on the upstream and downstream probe sets, presenting the relative relationship between GLS, KGA and GAC, and determining the glutamine metabolism type, thereby obtaining the detection results of cancer risk assessment.

[0148] In a preferred embodiment, the kit further comprises:

[0149] Liquid phase chip, coupled with corresponding capture probes, for detecting the prepared PCR products; and / or

[0150] The result presentation unit uses fluorescence to present the results; further preferably, the result presentation unit includes Luminex magnetic beads, which are used to couple the captured amplified target detection gene and emit a fluorescent signal with a corresponding intensity value on the surface.

[0151] For example, the result presentation unit can be designed for these markers using chemiluminescence or digital PCR methods.

[0152] A KGA and GAC recognition module can be designed and linked to different luminescence modules. Diagnosis can be made by quantifying luminescence and calculating the ratio of the two. Alternatively, the log2 (KGA / GAC) ratio can be used to quantify risk. This method is fast, low-cost, and suitable for community screening.

[0153] The present invention will be further described below through specific examples. It should be noted that the following examples are only for illustration and are not intended to limit the present invention.

[0154] Example 1

[0155] 1. Patient recruitment and blood sample processing

[0156] Based on the data from the inventor's cooperative hospital, 11 patients with hepatocellular carcinoma (HCC) diagnosed between January 2023 and March 2023 and 9 healthy controls from the physical examination department were selected. The hepatocellular carcinoma group included 10 males and 1 female; aged 45-71 years, median 54 years; the healthy control group included 8 males and 1 female; aged 49-78 years, median 62 years. There was no significant difference in age and gender between the two groups (P>0.05). Inclusion criteria for the patient group: (1) diagnosed by tissue biopsy, clinical stage A or stage B; (2) first diagnosed with hepatocellular carcinoma and not yet received treatment. Exclusion criteria: combined with other cancers.

[0157] 2. Sample preparation:

[0158] Clinical samples: Peripheral blood was collected from patients using anticoagulant blood collection tubes containing EDTA-K2, stored, and transported at 4°C. Leukocytes and plasma were separated using a multi-step centrifugation method: first, centrifugation was performed at 400g for 25 minutes at 4°C to collect the upper plasma layer and the middle layer of leukocytes. The upper plasma layer was centrifuged twice more: at 1600g for 15 minutes at 4°C and at 16,000g for 15 minutes at 4°C. The upper plasma layer was collected and frozen at -80°C. The middle layer of leukocytes was subjected to multi-step gradient centrifugation and red blood cell lysis to collect pure leukocytes. The cells were resuspended in RPMI1640 medium containing 10% calf serum and 10% DMSO, then frozen at 80°C for 24 hours and finally transferred to liquid nitrogen for storage.

[0159] Whole-transcriptome sequencing (RNA-seq) was performed on leukocytes from HCC patients and controls to determine the expression levels of the GLS gene and its two isoforms (in this example, log2(KGA / GAC) was used to represent the KGA / GAC ratio). The results, as shown in Figures 3A-3C, show that compared with the control group, GLS expression levels were significantly downregulated in HCC patients (Figure 3A), while the KGA / GAC ratio was significantly upregulated (Figure 3B). Both quantitative parameters can distinguish HCC patients from controls (i.e., can be used for cancer diagnosis; Figure 3C).

[0160] Example 2

[0161] A dataset similar to that of Example 1 was collected in the document “RNA-seq profiling reveals PBMC RNA as a potential biomarker for hepatocellular carcinoma” published by Han et al. [Han et al. Scientific Reports 2021; 11: 17797]. The document collected peripheral blood samples from 17 patients with liver cancer and 17 healthy controls, and used RNA-seq technology to study the gene expression profile of peripheral blood mononuclear cells (PBMCs). The inventors validated the method of the present invention based on the dataset in the document. The results are shown in Figures 4A-4C, which are consistent with the results of Example 1.

[0162] At the same time, the present inventors found that the expression of GLS can be combined with the KGA / GAC Ratio ( Figure 4D ) to achieve better diagnostic results: using the diagnostic parameters shown in the purple dotted box, the specificity was 94.1% (16 / 17) and the sensitivity was 76.5% (13 / 17).

[0163] Example 3

[0164] A peripheral blood leukocyte RNA-seq dataset was collected in the "Blood transcriptome analysis of patients with uncomplicated bacterial infection and sepsis" document published by Herwanto et al. [Herwanto et al. BMC Res Notes 2021 Feb 27; 14(1): 76], which included 12 patients with uncomplicated infection, 20 patients with sepsis (4 patients with post-treatment follow-up), 19 patients with septic shock (10 patients with post-treatment follow-up), and 40 healthy controls, for a total of 105 white blood cell samples. The present inventors used the peripheral blood leukocyte RNA-seq dataset in the document to validate the method of the present invention.

[0165] The results, shown in Figures 5 and 6, show that GLS expression was significantly downregulated in all infection patients, while the KGA / GAC ratio was upregulated. Furthermore, compared to pre-treatment, GLS expression was downregulated and the KGA / GAC ratio was upregulated in sepsis patients after treatment, while the opposite trend was observed in septic shock patients. These data demonstrate that the present invention can be used for the prediction and monitoring of infection patients.

[0166] Example 4

[0167] This embodiment provides a diagnostic kit comprising:

[0168] PCR plate, coated with poly-dT primers, used to capture mRNA in the sample to be tested;

[0169] An upstream and downstream probe set, comprising upstream and downstream probes of the detection markers screened by the above-described method, for specifically capturing the amplified target detection gene present in the sample to be tested on the PCR plate;

[0170] The result presenting unit is used to capture and amplify the target detection gene based on the upstream and downstream probe sets, and present the detection result using fluorescence.

[0171] Among them, for the GLS gene fragment, the primers were designed as follows:

[0172] Among them, GLS can be the sum of KGA and GLS, or it can be measured separately using the above primers.

[0173] Through evaluation, the accuracy of the kit of this embodiment can reach more than 90%.

[0174] Example 5

[0175] The basic scheme is the same as Example 3, except that the expression of genes such as GAPDH and ACTIN can be used as a reference to normalize the expression levels of GLS, GKA, and GAC, and the following Actin probe is used:

[0176] Example 6

[0177] Same as Example 3, except that it also includes:

[0178] Liquid phase chip, coupled with corresponding capture probes, used to detect the prepared PCR products;

[0179] The result presentation unit includes Luminex magnetic beads, which are used to couple the captured amplified target detection gene and emit a fluorescent signal with a corresponding intensity value on the surface.

[0180] Example 7

[0181] Same as Example 3, except that it also includes:

[0182] The result presentation unit designed by the digital PCR method can, for example, use the same primers as those used for qPCR, supplemented with the following probes: GAC: 5'-agaacttgctttaaaagagacagtatgg-3' (SEQ ID NO: 9; modified: 5'HEX, 3'MGB) KGA: 5'-tggaacagcgggactatga-3' (SEQ ID NO: 10; modified: 5'FAM, 3'MGB)

[0183] Example 8

[0184] This embodiment provides a kit for protein detection.

[0185] Currently, generic GLS antibodies (such as Abcam's Ab93434), KGA-specific antibodies (such as Proteintech's 20170-1-AP), and GAC-specific antibodies (such as Proteintech's 19958-1-AP) are commercially available. Therefore, free protein in the sample is quantitatively detected using techniques such as western blot, ELISA, and SIMOA. Based on the expression levels and / or expression relationships of GLS, KGA, and GAC described in the present invention, the risk of tumor or cancer development for the individual in the sample is determined.

[0186] The specific embodiments described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above are only specific embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A method for evaluating cancer risk, infection status, vaccine effect and / or drug effect based on glutamine metabolism pattern, characterized in that: The following steps are involved: Collect samples; The gene expression information of the glutamine metabolic pattern in the sample is detected, and the risk probability of the presence of tumors or cancerous cells in the human body of all the sample owners, infection conditions, vaccine effects and / or drug effects are evaluated based on the glutamine metabolic pattern.

2. The evaluation method according to claim 1, characterized in that: The sample is a genetic material sample containing gene expression information of glutamine metabolism pattern, i.e., a blood sample, a urine sample or a tissue sample; more preferably, it is a peripheral blood sample; more preferably, it is leukocytes, free RNA, free protein separated from the peripheral blood sample; and / or The gene expression information of the glutamine metabolic pattern of the sample is detected and quantified by RNA-seq technology, single-cell transcriptome technology, qPCR technology, digital PCR technology, ELISA technology, mass spectrometry and / or SIMOA technology.

3. The evaluation method according to claim 1 or 2, characterized in that: The gene expression information of the glutamine metabolic pattern of the sample includes: (i) the expression level of GLS, (ii) the expression level of KGA, (iii) the expression level of GAC, (iv) the ratio of KGA to GAC, further preferably log2 (KGA / GAC), and / or (v) the proportion of KGA or GAC in GLS; the glutamine metabolic pattern is determined based on some of the options.

4. The evaluation method according to claim 3, characterized in that: Specific methods for determining glutamine metabolism patterns based on some of the options include: (i) Based on the expression level of GLS and compared with the preset threshold, the risk probability of tumor or cancerous cells in all the samples, infection status, vaccine effect and / or drug effect are evaluated; (ii) Determine the glutamine metabolism pattern based on the expression relationship between KGA and GAC, i.e., the ratio / proportion of the two, or based on log2(KGA / GAC), and compare it with the preset threshold to evaluate the risk of tumor or cancer cells in all the samples, infection status, vaccine effect and / or drug effect; (iii) The expression level of GLS is comprehensively compared with the expression levels of KGA and GAC and the preset thresholds to evaluate the risk of tumor or cancerous cells in all the samples, infection status, vaccine effect and / or drug effect.

5. A composition of glutamine metabolism markers for evaluating the risk of tumors or cancerous cells in the body, infection status, vaccine efficacy and / or drug effect, characterized in that: include: The first marker is used to mark the expression of GLS; The second marker is used to mark the expression of KGA; The third marker is used to mark the expression of GAC; The evaluation of the risk of tumor or cancerous cells in the body, infection status, vaccine effect and / or drug effect is achieved based on only one or more of the compositions.

6. A nucleic acid library of glutamine metabolism markers for evaluating the risk of tumors or cancerous cells in the body, infection status, vaccine efficacy and / or drug effect, characterized in that: include: The first marker is used to mark the expression of GLS; The second marker is used to mark the expression of KGA; The third marker is used to mark the expression of GAC; Among them, the evaluation of the risk probability of tumor or cancerous cells existing in the body, infection status, vaccine effect and / or drug effect is achieved only based on one or more of the first marker, the second marker and the third marker.

7. A cancer risk assessment system, characterized in that: include: A nucleic acid detection module, used for performing qualitative or quantitative gene detection on samples containing nucleic acid; A nucleic acid library, comprising the nucleic acid library as claimed in claim 6; An evaluation module is used to determine the risk probability of tumor or cancerous cells in all the samples, infection status, vaccine effect and / or drug effect based on the evaluation method as described in any one of claims 1 to 4.

8. A cancer risk assessment method based on glutamine metabolism pattern, characterized in that: The following steps are involved: Collect samples; detecting gene expression information of glutamine metabolism pattern of the sample; A pre-trained machine learning model is used to evaluate the risk probability of the presence of tumors or cancerous cells in all the sample owners; wherein the machine learning model is trained using the expression levels and / or expression relationships of GLS, KGA and GAC as labels, and the input of the machine learning model is the gene expression information of the glutamine metabolic pattern of the sample; the machine learning model includes KNN, support vector machine, logistic regression, decision tree, random forest, and naive Bayes classification models.

9. A kit based on glutamine metabolism model, characterized in that: The kit determines the risk probability of tumor or cancerous cells existing in all the samples by only capturing the expression amount and / or expression relationship of GLS, KGA and GAC in the leukocytes, free RNA or free protein of the sample to be tested.

10. The kit according to claim 9, characterized in that The kit includes upstream and downstream primers for specifically capturing the genes present in the sample to be tested and determining the expression levels and / or expression relationships of GLS, KGA and GAC; Preferably, the upstream and downstream primer pairs are as follows: For KGA, 5′-actggagatgtgtctgcac-3′ (Forward, SEQ ID NO: 1) and 5′-gcaggcttccagcaaaaat-3′ (Reverse, SEQ ID NO: 2) were used; and / or For GAC, 5'-ttggactatgaaagtctccaac-3' (Forward, SEQ ID NO: 3) and 5'-ccattctatatactacagttgtagagat-3' (Reverse, SEQ ID NO: 4) were used; and / or For GLS, the following primers were used: 5'-atgcattcctgtggcatgt-3' (Forward, SEQ ID NO: 5) and 5'-ctgttgcccatcttatccagag-3' (Reverse, SEQ ID NO: 6); and / or The expression levels of GLS, GKA, and GAC were normalized using Actin probes: 5′-agagctacgagctgcctgac-3′ (Forward, SEQ ID NO: 7) and 5′-agcactgtgttggcgtacag-3′ (Reverse, SEQ ID NO: 8); Preferably, the kit further comprises a PCR plate coated with poly-dT primers and provided with sites for detecting GLS, KGA and GAC; Preferably, the kit further comprises a result presentation unit for presenting the relative relationship between GLS, KGA and GAC based on the result of capturing and amplifying the target detection gene by the upstream and downstream primers, and determining the glutamine metabolism pattern, thereby obtaining the detection result of cancer risk assessment; Preferably, the kit further comprises: A liquid phase chip coupled with corresponding capture probes for detecting the prepared PCR products; and / or The result presentation unit uses fluorescence to present the result; further preferably, the result presentation unit includes Luminex magnetic beads, which are used to couple the captured amplified target detection gene, and emit a fluorescent signal of a corresponding intensity value on the surface; and / or The result presentation unit is designed for the marker using chemiluminescence or digital PCR methods; preferably, KGA and GAC recognition modules are designed and linked to different luminescence modules, and the luminescence is quantified and the ratio of the two is calculated to perform diagnosis; or the risk is quantitatively expressed based on log2 (KGA / GAC).

Citation Information

Patent Citations

  • Application of GLS in making liver cancer diagnosis and prognosis evaluation kit

    CN105349622A

  • Application of GLS1 enzyme in preparing liver cancer diagnostic kit

    CN105372432A

  • Application of metabolic marker, Parkinson's disease diagnosis model and diagnosis device

    CN115714027A

  • Glutamine metabolism pattern-based cancer risk assessment method and application thereof

    CN117286248A